Literature DB >> 1707951

The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants.

D Lyn1, D S Gill, R A Scroggs, A Portner.   

Abstract

The complete nucleotide sequence of the nucleoprotein (NP) gene of human parainfluenza virus type 1 (hPIV-1) was determined from a cDNA clone of mRNA. The mRNA is 1683 nucleotides long (excluding polyadenylic acid) and encodes a protein of 524 amino acids with a predicted Mr of 57,548. An amino acid identity of 83% was predicted between the NPs of the human pathogen hPIV-1 and the murine paramyxovirus, Sendai virus, compared to 72% similarity at the level of the nucleotide sequence. In contrast, the amino acid sequence identity between the NPs of hPIV-1 and hPIV-3 was 59%, suggesting a more distant evolutionary relationship. The NP amino acid sequences of hPIV-1 and Sendai virus were highly conserved in the amino-terminal half of the molecule, in which 395 of the first 420 amino acids were identical. Of 11 monoclonal antibodies (MAbs) targeted against the Sendai virus NP, five cross-reacted with the hPIV-1 NP. The MAbs that cross-reacted recognize epitopes within regions of high amino acid similarity between the NPs of the two viruses. Also, five of the eight MAbs raised against hPIV-1 NP cross-reacted with Sendai virus NP. Taken together, our observations suggest that the essential amino acid sequence determinants of the NP structures of hPIV-1 and Sendai virus are conserved despite changes in their nucleotide sequences during evolution. This implies that there was a selective pressure to maintain the important functional domains of the protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707951     DOI: 10.1099/0022-1317-72-4-983

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Crystallization of biologically active hemagglutinin-neuraminidase glycoprotein dimers proteolytically cleaved from human parainfluenza virus type 1.

Authors:  T Takimoto; W G Laver; K G Murti; A Portner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.

Authors:  R Sealy; B G Jones; S L Surman; J L Hurwitz
Journal:  Vaccine       Date:  2010-08-01       Impact factor: 3.641

3.  The hypervariable C-terminal tail of the Sendai paramyxovirus nucleocapsid protein is required for template function but not for RNA encapsidation.

Authors:  J Curran; H Homann; C Buchholz; S Rochat; W Neubert; D Kolakofsky
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut.

Authors:  Rajeev Rudraraju; Sherri Surman; Bart Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Virology       Date:  2011-01-11       Impact factor: 3.616

5.  Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Authors:  Elisabeth Adderson; Kristen Branum; Robert E Sealy; Bart G Jones; Sherri L Surman; Rhiannon Penkert; Pamela Freiden; Karen S Slobod; Aditya H Gaur; Randall T Hayden; Kim Allison; Nanna Howlett; Jill Utech; Jim Allay; James Knight; Susan Sleep; Michael M Meagher; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Clin Vaccine Immunol       Date:  2014-12-31

6.  Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Authors:  Laura E Luque; Olga A Bridges; John N Mason; Kelli L Boyd; Allen Portner; Charles J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

8.  Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Authors:  Toru Takimoto; Julia L Hurwitz; Chris Coleclough; Cecilia Prouser; Sateesh Krishnamurthy; Xiaoyan Zhan; Kelli Boyd; Ruth A Scroggs; Brita Brown; Yoshiyuki Nagai; Allen Portner; Karen S Slobod
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Authors:  Bart G Jones; Robert E Sealy; Sherri L Surman; Allen Portner; Charles J Russell; Karen S Slobod; Philip R Dormitzer; John DeVincenzo; Julia L Hurwitz
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

Review 10.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.